MedMira's HIV Test Approved Under USAID Initiative
Allows for International Purchase as Part of US Presidential Plan for AIDS Relief
USAID's office of HIV/AIDS is responsible for leading the Agency's efforts within the President's Emergency Plan for AIDS Relief ("PEPFAR"); a $15 billion multifaceted approach to combating HIV and AIDS in over 100 countries, with particular emphasis on fifteen focus countries in Africa, Asia and Latin America. MedMira's inclusion on this procurement list enables Reveal G3 to be purchased for USAID-funded projects, and permits countries receiving USAID funding to purchase Reveal G3 under the PEPFAR program.
In order to be included on the USAID Procurement List, a rapid HIV test must meet certain performance specifications which, in turn, offers both the agency and the purchaser assurances that the product to be purchased is of the highest quality, safety and efficacy. Reveal G3 is the most advanced test in MedMira's Reveal product line, and was approved by the US Food and Drug Administration (FDA) only last year. Reveal G3 is one of only five products on the USAID list having FDA approval, thus offering purchasers of the test yet another level of confidence in product performance and quality.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.